These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 11426526)
1. Continuous infusion of vincristine-doxorubicin with bolus of dexamethasone(VAD) alternated with CHEP in the treatment of patients over 60 years old with aggressive non-Hodgkin's lymphoma. Cartron G; Voillat L; Desablens B; Le Maignan C; Milpied N; Foussard C; Dugay J; Maakaroun A; De Muret A; Colombat P; Leuk Lymphoma; 2001 Feb; 40(5-6):529-40. PubMed ID: 11426526 [TBL] [Abstract][Full Text] [Related]
2. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M; Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026 [TBL] [Abstract][Full Text] [Related]
3. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764 [TBL] [Abstract][Full Text] [Related]
4. Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B. Lichtman SM; Niedzwiecki D; Barcos M; Carlisle TL; Cooper MR; Johnson JL; Peterson BA Ann Oncol; 2000 Sep; 11(9):1141-6. PubMed ID: 11061609 [TBL] [Abstract][Full Text] [Related]
5. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505. Itoh K; Ohtsu T; Fukuda H; Sasaki Y; Ogura M; Morishima Y; Chou T; Aikawa K; Uike N; Mizorogi F; Ohno T; Ikeda S; Sai T; Taniwaki M; Kawano F; Niimi M; Hotta T; Shimoyama M; Tobinai K; Ann Oncol; 2002 Sep; 13(9):1347-55. PubMed ID: 12196359 [TBL] [Abstract][Full Text] [Related]
6. Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study. Gaynor ER; Unger JM; Miller TP; Grogan TM; White LA; Mills GM; Balcerzak SP; Varterasian M; LeBlanc M; Fisher RI J Clin Oncol; 2001 Feb; 19(3):750-5. PubMed ID: 11157027 [TBL] [Abstract][Full Text] [Related]
7. CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas. Pan D; Qin J; Farber C; O'Brien J; Filippa D; Portlock CS Leuk Lymphoma; 2003 Jun; 44(6):967-71. PubMed ID: 12854895 [TBL] [Abstract][Full Text] [Related]
8. Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: treatment results and prognostic factor analysis in a multi-centre trial. Köppler H; Pflüger KH; Eschenbach I; Pfab R; Birkmann J; Zeller W; Holle R; Steinhauer UE; Gropp C; Oehl S Ann Oncol; 1994 Jan; 5(1):49-55. PubMed ID: 8172793 [TBL] [Abstract][Full Text] [Related]
9. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014 [TBL] [Abstract][Full Text] [Related]
10. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma. Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561 [TBL] [Abstract][Full Text] [Related]
11. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen]. Huang HQ; Jiang WQ; Wang W; Zhou ZM; Xia ZJ; Lin XB; Li YH; Xu RH; Zhang L; Xu GC; Sun XF; Liu DG; He YJ; Guan ZZ Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma. Wilder DD; Ogden JL; Jain VK Clin Lymphoma; 2002 Mar; 2(4):229-37. PubMed ID: 11970762 [TBL] [Abstract][Full Text] [Related]
13. Phase III trial of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) versus cisplatin, etoposide, bleomycin and prednisone (CisEBP) for the treatment of advanced non-Hodgkin's lymphoma of high grade malignancy. The Danish Lymphoma Study Group. Andersen J; Thorling K; Bentzen SM; Brincker H; Christensen BE; Pedersen M Acta Oncol; 1990; 29(8):995-9. PubMed ID: 1703769 [TBL] [Abstract][Full Text] [Related]
14. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. Sonneveld P; de Ridder M; van der Lelie H; Nieuwenhuis K; Schouten H; Mulder A; van Reijswoud I; Hop W; Lowenberg B J Clin Oncol; 1995 Oct; 13(10):2530-9. PubMed ID: 7595704 [TBL] [Abstract][Full Text] [Related]
15. Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkin's lymphoma--a phase II study. Späth-Schwalbe E; Lange C; Genvresse I; Krüger L; Eucker J; Schweigert M; Sezer O; Budach V; Possinger K Anticancer Drugs; 2002 Apr; 13(4):395-403. PubMed ID: 11984085 [TBL] [Abstract][Full Text] [Related]
16. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. Gutierrez M; Chabner BA; Pearson D; Steinberg SM; Jaffe ES; Cheson BD; Fojo A; Wilson WH J Clin Oncol; 2000 Nov; 18(21):3633-42. PubMed ID: 11054436 [TBL] [Abstract][Full Text] [Related]
18. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386 [TBL] [Abstract][Full Text] [Related]
19. [Long term results for intermediate and high grade localized non Hodgkin lymphoma, treated with chemotherapy and radiotherapy]. Ramírez V P; Ocqueteau T M; Alvarez Z M; Bertín C-M P; Lira V P; Bustos C M; Besa de C P Rev Med Chil; 2006 Nov; 134(11):1409-16. PubMed ID: 17277854 [TBL] [Abstract][Full Text] [Related]